If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.

Eye abnormalities linked to metal deficiencies in children with thalassemia receiving frequent transfusions

Jaipur: A study by doctors at the govt-run JK Lon Hospital has found that nearly 43% of children with thalassemia who undergo ...

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
The Clinton Herald

TO YOUR GOOD HEALTH: Surgery is prudent if conservative treatment of neuroma fails

I am a 68-year-old woman who is in relatively good health. My primary exercise is walking my dogs anywhere from 2-5 miles per day. I have two ...
TipRanks on MSN

Bristol-Myers Squibb’s Luspatercept Study: A Potential Game-Changer for Alpha-Thalassemia

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Vertex Pharmaceuticals Incorporated: Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK at the North American Cystic Fibrosis Conference

Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly ...